A5066812528- Virus-based gene therapy research
- CAR-T cell therapy research
- Cancer Research and Treatments
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Autophagy in Disease and Therapy
- Cancer Immunotherapy and Biomarkers
- Animal Genetics and Reproduction
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Head and Neck Surgical Oncology
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Glioma Diagnosis and Treatment
- interferon and immune responses
- Gear and Bearing Dynamics Analysis
- Immune Cell Function and Interaction
- Immune cells in cancer
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- bioluminescence and chemiluminescence research
- Renal and related cancers
Guangxi Normal University
2025
The University of Texas MD Anderson Cancer Center
2015-2024
Xinjiang University
2004-2024
Renmin Hospital of Wuhan University
2017-2024
Zhuhai People's Hospital
2024
Jinan University
2024
Macau University of Science and Technology
2024
Wuhan University
2017-2024
European School of Oncology
2023
Zhejiang University
2021-2022
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined oral and of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) (n = 53) followed by programmed death-1 (PD-1) at progression 46), analyzed signatures longitudinal tissue...
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
Oncolytic viruses selectively lyse tumor cells, disrupt immunosuppression within the tumor, and reactivate antitumor immunity, but they have yet to live up their therapeutic potential. Immune checkpoint modulation has been efficacious in a variety of cancer with an immunogenic microenvironment, is associated toxicity due nonspecific T-cell activation. Therefore, combining these two strategies would likely result both effective specific therapy. To test hypothesis, we first constructed...
Inflammation is a major risk factor for pancreatic ductal adenocarcinoma (PDAC). When occurring in the context of pancreatitis, KRAS mutations accelerate tumor development mouse models. We report that long after its complete resolution, transient inflammatory event primes epithelial cells to subsequent transformation by oncogenic KRAS. Upon recovery from acute inflammation, display an enduring adaptive response associated with sustained transcriptional and epigenetic reprogramming. Such...
Oncolytic adenoviruses are promising therapies for the treatment of gliomas. However, untargeted viral replication and paucity coxsackie-adenovirus receptors (CARs) on tumor cells major stumbling blocks adenovirus-based treatment. We studied antiglioma activity tumor-selective Delta-24 adenovirus, which encompasses an early 1 A adenoviral (E1A) deletion in retinoblastoma (Rb) protein-binding region, Delta-24-RGD adenovirus. has RGD-4C peptide motif inserted into fiber, allows adenovirus to...
The eradication of brain tumor stem cells is essential for long-term remission after treatment. In this study, we examined the therapeutic potential an oncolytic adenovirus, Delta-24-RGD, targeted to abnormal p16INK4/Rb pathway in cells. Four cell lines from surgical glioblastoma specimens expressed high levels adenoviral receptors and allowed efficient viral infection, replication, oncolysis Rb-dependent manner. Delta-24-RGD induced autophagic death, as indicated by accumulation Atg5 LC3-II...
Background: Interindividual differences in the structure and expression of dopamine receptor genes affect availability may be genetic basis for variation vulnerability to tobacco smoking. In this study, prevalences polymorphisms TaqIA allele (A1 A2) TaqIB (B1 B2) D2 gene 157 lung cancer case patients 126 control subjects were determined assess whether individuals homozygous or heterozygous less common A1 B1 alleles are more vulnerable nicotine addiction. Methods: Case accrued from an ongoing...
Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response not been thoroughly elucidated. To better understand this, we studied a large cohort melanoma patients treated with targeted therapy or checkpoint blockade (n = 60). Heterogeneity therapeutic responses via radiologic assessment was observed majority patients. Synchronous metastases were analyzed deep profiling, revealed substantial all studied, considerable...
Oncolytic adenoviruses, such as Delta-24-RGD, are promising therapies for patients with brain tumor. Clinical trials have shown that the potency of these cancer-selective adenoviruses should be increased to optimize therapeutic efficacy. One potential strategy is increase efficiency adenovirus-induced cell lysis, a mechanism has not been clearly described. In this study, first time, we report autophagy plays role in lysis. At late stage after adenovirus infection, numerous autophagic...
Emerging evidence suggests anti-cancer immunity is involved in the therapeutic effect induced by oncolytic viruses. Here we investigate of Delta-24-RGD adenovirus on innate and adaptive anti-glioma immunity.Mouse GL261-glioma model was set up immunocompetent C57BL/6 mouse for treatment. The changes immune cell populations were analyzed immunohistochemistry flow cytometry. evaluated with functional study splenocytes isolated from mice. efficacy virotherapy assessed animal survival analysis....
Abstract Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as solid therapeutic approach. Delta-24-RGD replication competent adenovirus engineered to replicate tumor cells with an aberrant RB pathway. This virus has proven be safe effective adult gliomas. Here we report that the administration mice results significant increase survival...
Our understanding is limited concerning the tumor immune microenvironment of inflammatory breast cancer (IBC), an aggressive form primary with low rates pathologic complete response to current neoadjuvant chemotherapy (NAC) regimens. We retrospectively identified pretreatment (N = 86) and matched posttreatment tissue 27) from patients stage III or de novo IV IBC who received NAC followed by a mastectomy. Immune profiling was performed including quantification lymphoid myeloid infiltrates IHC...
Novel therapies are clearly needed for the treatment of gliomas, and strategies that involve combining oncolytic vectors with chemotherapy hold out significant hope a more effective this malignancy. Whether acts directly on tumor cells by inducing cell arrest or death, indirectly blocking angiogenesis, resulting delay in growth may provide virus wider window opportunity to overcome challenge imposed kinetics tumor. In study we sought determine whether adenovirus Delta-24-RGD, combination...
Autophagy is a protective mechanism that renders cells viable in stressful conditions. Emerging evidence suggests this cellular process also tumor suppressor pathway. Previous studies showed cyclin-dependent kinase inhibitors (CDKI) induce autophagy. Whether retinoblastoma protein (RB), key and downstream target of CDKIs, induces autophagy not clear. Here, we show RB triggers the activators p16INK4a p27/kip1 an RB-dependent manner. binding to E2 transcription factor (E2F) required for...
We report the design, synthesis, and optimization of first, selective activators cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, soluble myosin were designed culminating in discovery omecamtiv mecarbil (24). Compound 24 is currently clinical trials for treatment systolic heart failure.
The study sought to evaluate the safety and efficacy of FIREHAWK, a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent (SES) for treating patients with single de novo coronary lesions compared durable everolimus-eluting (EES) XIENCE V.A total 458 native ≤24 mm in length artery ≥2.25 ≤4.0 diameter were enrolled TARGET I study, prospective, randomised, non-inferiority trial. primary endpoint was in-stent late lumen loss (LLL) at nine-month follow-up. secondary...
Abstract China's South–North Water Transfer Project (SNWTP) is a vast and still expanding network of infrastructure institutions that moves water from the Yangtze River its tributaries to cities in North China. This article aims assess SNWTP's impacts by beginning answer seven questions about project: How management SNWTP evolving? What are problems be resolved when managing within jurisdictions? status quality SNWTP? consequences resettlements caused increased supply affecting regional...